Recent News

The latest news from the governments, medical industry and top online sources.

Lexeo reports positive phase 1/2 data for LX2020

Regulatory progress supports accelerated approval pathway Lexeo Therapeutics has reported positive interim results from its ongoing phase 1/2 HEROIC-PKP2 clinical trial evaluating LX2020 in patients with PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), alongside a regulatory update that may support an accelerated approval pathway. The company said LX2020 was generally well tolerated across 10 participants treated in the […]

Meeting highlights from the Pharmacovigilance Risk Assessmen…

PRAC starts review of depression and anxiety medicine Deanxit (flupentixol/melitracen) PRAC has started a review of Deanxit, a fixed-dose combination medicine for treating depression and anxiety, following reports of serious neurological and psychiatric side effects in patients taking the medicine. The reports concern cases involving movement disorders, such as tremors, stiffness, restlessness and involuntary movements, […]

Radiotherapy boosts progression‑free survival in advanced lu…

SARON trial shows 56% improvement over standard treatment Patients with oligometastatic non‑small cell lung cancer lived significantly longer without disease progression when radiotherapy was added to standard systemic therapy, according to new phase 2 data presented at the ESMO Congress 2026. The SARON trial, funded by Cancer Research UK and sponsored by UCL, found progression‑free […]

Meeting highlights from the Committee for Veterinary Medicin…

CVMP opinions on veterinary medicinal products The Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Bovilis Lumpyvax (lumpy skin disease vaccine (live)), for the active immunisation of cattle to reduce clinical signs and viraemia caused by lumpy skin disease virus. The Committee adopted a positive opinion for a marketing authorisation for Stemyca (equine […]

NICE backs Tryngolza for FCS treatment

Guidance supports use when standard therapies fail NICE has issued final draft guidance recommending Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome, but only when response to diet and conventional triglyceride‑lowering treatments has been inadequate. FCS is an ultra‑rare inherited lipid disorder marked by severe hypertriglyceridaemia and a high […]

Meeting highlights from the Committee for Medicinal Products…

12 new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its September 2026 meeting. The committee recommended granting a marketing authorisation for Frehemgo (denecimig), for the prophylaxis of bleeding episodes in patients with haemophilia A, an inherited bleeding disorder caused by a lack of factor VIII, a protein […]

Study highlights advance in influenza protection for older a…

Phase 3 data supports combined vaccine technologies CSL Seqirus has announced publication of pivotal phase 3 results for its MF59‑adjuvanted cell‑based higher‑dose quadrivalent influenza vaccine in The Lancet Infectious Diseases, marking what the company describes as an important milestone in influenza prevention for older adults. The trivalent formulation of the vaccine, marketed as AUJEMFLU, was […]

NICE backs Axhidrox for severe underarm sweating

First guidance for a licensed hyperhidrosis treatment NICE has recommended Axhidrox (glycopyrronium bromide) cream for routine NHS use in adults with severe primary axillary hyperhidrosis whose symptoms are not adequately controlled with lifestyle advice, topical aluminium‑based antiperspirants or oral antimuscarinic medicines, or for whom these options are contraindicated or not tolerated. The decision marks the […]

New leadership team appointments | European Medicines Agency…

Ivo Claassen joined EMA in 2018. Among many career highlights, Ivo and his team worked with the veterinary medicines network on the successful implementation of the 2019 Veterinary Medicinal Products Regulation. Ivo’s commitment to public and animal health, his outstanding leadership and contribution to the veterinary medicines network leave an indelible mark on the Agency’s […]

Vista trial begins dosing in precision cancer vaccine study

First-in-human evaluation of infinitopes’ therapeutic platform Infinitopes has dosed the first patient with ITOP1, its lead investigational therapeutic cancer vaccine, marking the first clinical evaluation of the company’s Precision Immunomics platform. The approach combines immunopeptidomic antigen discovery with engineered viral vector technologies to identify naturally presented tumour antigens capable of generating durable anti‑tumour T‑cell responses. […]